AL, ATTRwt and ATTRv amyloidosis each tell a different story #ASH24 #amyloidosis #ASHKudos to all in the ASH Amyloid Guidelines panel for taking on the rigorous scoping analysis

The unexpected withdrawal of #VOXELOTOR for sickle cell disease shocked everyone. 👉🏾MUST-READ interview w/ experts Alexis Thompson John Strouse 🚩attend Monday 1030am Room 33 convention center ASH ashpublications.org/ashnewsdaily/b…

A snapshot of the energy and camaraderie fueling #ASH24 AmericanJournalofHematology ASH Vincent Rajkumar Naseema Gangat

Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 Thanos Dimopoulos NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.10… Slides in thread

Best things happen with best partners Joselle Cook #ASH24

Read ➡️ how my mentor Vincent Rajkumar persisted and collaborated in #SMM early intervention trials, culminating into the landmark AQUILA trial #ASH24 So much to learn from his experience

The @MayoMyeloma group #ASH24 Also missing RahmaWarsame MD . Wilson Gonsalves. Eli Muchtar. Erin Weidmeier

Symptoms DO matter Important publications by my friend and colleague Nadine Abdallah

The very first paper from the iStopMM study was published in Blood Cancer Journal in 2021 and describes the design of the study. iStopMM is the first population-based MGUS screening study and a randomized trial of follow-up strategies. 📊🔬🧵👇 #iStopMM #MMsm

Calling all hematologists! Apply to join the dynamic ASH News Daily team, where we break down the ASH meeting into engaging and easy-to-read insights ASH ashpublications.org/ashnewsdaily/p…

What an incredible community for #MM patients and their families International Myeloma Foundation thank you for having me

Excellent work and an important piece of data by Arwa Bohra (she/her) 👏👏Translating Peripheral blood flow data into meaningful thresholds aligning with the peripheral smear-based criteria for PCL. 1.2% CPCs by flow ≈ 5% CPCs by smear @MayoMyeloma

If approved, patients with high risk smoldering myeloma will have a choice that can delay progression to active myeloma and highly likely to prolong life. More on the CHMP decision here: globenewswire.com/news-release/2…

Register and attend: The 2nd Annual Kyle Barlogie Plasma Cell Disorders Symposium featuring top myeloma experts from Mayo Clinic and Memorial Sloan Kettering Cancer Center Info and registration link: web.cvent.com/event/3197041a… Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Shaji Kumar

Extramedullary disease versus paraskeletal disease – is there a biological difference? Saurabh Zanwar (Mayo Clinic Hematology-Oncology Fellowship) answers this question at #iwHRMM25 #Myeloma #MultipleMyeloma #MMsm

Updates mSMART guidelines for newly diagnosed myeloma. Also updated risk-stratification.

Our incredible ASH News Daily team! Be sure to read the preview articles of whats happening for #ASH25 Saurabh Zanwar Ajay Major, MD, MBA Christopher Graham Supriya Gupta, MD Ayo S Falade, MD, MBA, APGD Chris Brierly Sarah Sewaralthahab, MD, MPH, ABIM

📰 Your official #ASH25 news is here! The preview issue of #ASHNewsDaily is now live, with teasers of some can’t-miss sessions. 🧵 First up: Editor-in-Chief Joselle Cook welcomes you to the annual meeting! 🔗 ow.ly/xem350XvN0X 1/6

Joselle Cook Dr. Christina Abrams previews the Special Interest session about guiding #sicklecell disease patients considering gene therapy. 🔗We’re Off to See the Wizard: Curative and Transformative Therapy for Sickle Cell Disease ow.ly/bWMq50XvN4Q #ASH25 #ConquerSCD 3/6

Joselle Cook Christopher Graham Supriya Gupta, MD Ajay Major, MD, MBA Join Sarah Sewaralthahab, MD, MPH, ABIM to explore the classical hematology sessions sure to have a full house — including a guidelines session, abstract presentation, and Education Program session. 🔗#ASH25 Through the Lens of a Classical Hematologist: ow.ly/NNVM50XvN8z 6/6